IDEAYA Biosciences (IDYA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$1.22
- Estimate
- -$1.05
- Surprise
- -16.2%
- Revenue (period 2026-06-30)
- $8.9M
- Score today
- 4.8/10
Revenue source: mixed.
How the report landed
IDEAYA Biosciences (IDYA) reported a wider loss than forecast — diluted EPS of -$1.22 against the -$1.05 estimate (a 16.2% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates IDYA Sell at 4.8/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -16.2% surprise compares with a +78.2% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Concentration risk — Pipeline: darovasertib
- Quality below floor (2.0 < 4.0)
- Momentum score 3.6/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $39.86
- Price target
- $45.37
- Stop
- $37.07
- Upside to target
- +13.8%
- Reward-to-risk
- 1.3:1
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
IDYA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.85B
- P/E (fwd)
- -9.7
- 52-week range
- $23.23–$42.68
- Off 52-week high
- 6.6%
- RSI (14)
- 68
- Volume vs avg
- 0.63×
- Score today
- 4.8/10